You are here: Industry Insights > gilead

News List

Gilead's Preclinical Combo Trial Might Eradicate HIV biospace
March 06, 2018
To date, treatments for HIV/AIDS have done a remarkable job of controlling the disease, but nothing has been able to totally eradicate the presence of the AIDS virus in patients’ bodies.
Viiv files HIV drug patent infringement lawsuit against Gilead pharmaceutical-technology
February 11, 2018
GSK-owned Viiv healthcare has filed a lawsuit against Gilead, the American biopharma company, for an alleged patent infringement of an HIV drug which has been newly approved.
Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short fiercepharma
February 09, 2018
Gilead Sciences' once-high-flying hepatitis C drugs have come a long way down since their peak sales years, but thanks to new competition from AbbVie, the company's important franchise will have another rough year in 2018.
Gilead's Biktarvy wins megablockbuster HIV nod fiercepharma
February 09, 2018
and rival GlaxoSmithKline strikes back...
AIDS charity lambasts “ethically challenged” Gilead over price hikes pharmafile
January 12, 2018
The AIDS Healthcare Foundation (AHF) has strongly criticised Gilead prices increases across the board for its HIV and AIDS treatment, including pre-exposure prophylaxis (PrEP) drug Truvada.
2018: Gilead is Not Done Shopping biospace
January 11, 2018
One of last year’s big stories was Gilead Sciences acquiring Kite Pharma for about $11.9 billion in late August.
Gilead’s patent for ‘Hepatitis C’ be challenged by MSF biospectrumasia
December 19, 2017
MSF challenges Gilead’s patent application for hepatitis C combination treatment in China, to bring down prices
Gilead could make a move for Galapagos within weeks pharmaphorum
December 18, 2017
The share price of Belgium-Dutch biotech Galapagos is rising thanks to renewed speculation that Gilead may be poised to acquire it.
Gilead backs $60M Hookipa round to fund immunotherapy R&D fiercebiotech
December 12, 2017
Gilead has joined Boehringer Ingelheim and Takeda on the list of investors in Hookipa Biotech.
Gilead makes $567m strategic acquisition for next-gen CAR-T pharmafile
December 11, 2017
It’s only four months since Gilead completed its buy-out of Kite Pharma for $11.9 billion, but it’s already moving quickly to establish bolt-on technology to take its CAR-T therapy forward.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page